Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yangxinshi Tablet for Chronic Coronary Syndrome
NCT06171061Phase 4Recruiting
- Sponsor
- Shandong First Medical University
- Start
- Dec 2023
- Primary completion
- Dec 2025
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of yangxinshi in Chronic Coronary Syndrome (CCS) (2 arms), sponsored by Shandong First Medical University. Primary endpoint: 6-minute walking distance at 24 weeks. Started Dec 2023; status: recruiting.
02
Drugs
yangxinshi
03
Conditions
Chronic Coronary Syndrome (CCS)
Beyond the preview
Go deeper on NCT06171061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06171061.